TG Therapeutics Stock Rises on Strong Briumvi Sales and Raised Guidance
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.
GlobalFoundries announces acquisition of Synopsys' ARC Processor IP Solutions to accelerate Physical AI development and expand RISC-V capabilities for next-gen applications.
Citigroup's (C) Q4 2025 profit fell 13% due to Russia exit loss, but investment banking fees surged 35% and adjusted earnings beat estimates as CEO Fraser's turnaround gains traction.
Honeywell's quantum computing unit Quantinuum prepares for IPO filing with $11B valuation, backed by Nvidia and major investors for breakthrough computing technology.
China's market regulator probes Trip.com Group for antitrust violations, accusing the dominant travel platform of abusing market power. Shares drop 6.5% as investigation unfolds.
Bank of America surpassed expectations, reporting a profit of $7.6 billion. High interest and trading helped, and the CEO remains optimistic.